Redundant manufacturing pathways are the only shield against sudden CDMO compliance failures.
Filing drug applications with multiple independent manufacturing facilities protects approval timelines from being derailed by a single partner's regulatory infractions.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Scholar Rock insulated its U.S. approval timeline from a sudden manufacturing partner failure by shifting focus to an alternate, pre-approved production facility.
By listing a second, alternate U.S.-based facility, Scholar Rock was able to drop a troubled CDMO and preserve its FDA approval timeline.
By removing a troubled third-party contract manufacturer and advancing solely with an alternate established facility, the company shielded its regulatory review from being derailed.
Scholar Rock successfully protected its regulatory timeline from a primary manufacturing site's failure by strategically including a redundant fill-finish option.
The presence of an alternate facility successfully insulated the US BLA review from the primary CDMO's failure, though the single-site European app had to be withdrawn.